NCT02913118

Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia

Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 462 (estimated)
• Sponsor: Qingfeng Pharmaceutical Group · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia: A Multicenter, Randomized,Double-blinded, Placebo Controlled Clinical Trial. The hypothesis is that combination therapy with Andrographolid Sulfonatein injection and antibacterial is significantly better than antibacterial alone in achieving clinical stability among hospitalized CAP patients.

Conditions

• Community Acquired Pneumonia

Interventions

Type	Name	Description
DRUG	Andrographolid Sulfonate Injection (AS Injection)
DRUG	Cephalosporin
DRUG	Azithromycin, Minocycline or Doxycycline
DRUG	Amoxicillin-clavulantic acid
DRUG	Fluoroquinolones
DRUG	Placebo

Timeline

• Start date: 2016-07-01
• Primary completion: 2019-01-01
• Completion: 2019-06-30
• First posted: 2016-09-23
• Last updated: 2018-04-10

Locations

16 sites across 1 country: China